NEW YORK: Pfizer readjusted its communications strategy for its anti-smoking drug Chantix on the heels of concern regarding its possible side effects.
Last month, the FAA banned pilots from taking Chantix after a report from Drug and Therapeutics Bulletin, a drug evaluation journal, linked the drug to seizures and loss of consciousness.
Ray Kerins, VP of worldwide communication and head of global media relations for the New York-based drugmaker, however, denied that any specific event triggered additional measures.
“We've had ...